Kuzuya, M. (2024). Drug-related sarcopenia as a secondary sarcopenia. Geriatrics & Gerontology International, 24(2), 195–203. https://pubmed.ncbi.nlm.nih.gov/38158766/
Gupta, A., & Gupta, Y. (2013). Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian Journal of Endocrinology and Metabolism, 17(5), 913–916. https://pubmed.ncbi.nlm.nih.gov/24083177/
Prokopidis, K., Giannos, P., Reginster, J. Y., et al. (2023). Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 14(2), 671–683. https://pubmed.ncbi.nlm.nih.gov/36781175/
Zhang, H., Qi, G., Wang, K., et al. (2024). A review on associated factors and management measures for sarcopenia in type 2 diabetes mellitus. Medicine (Baltimore), 103(16), e37666. https://pubmed.ncbi.nlm.nih.gov/38640276/
Duarte, M. P., Almeida, L. S., Neri, S. G. R., et al. (2024). Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 15(2), 501–512. https://pubmed.ncbi.nlm.nih.gov/38263952/
Chen, R., Zhang, L., Zhang, M., et al. (2023). Prevalence of sarcopenia and its association with clinical outcomes in heart failure: An updated meta-analysis and systematic review. Clinical Cardiology, 46(3), 260–268. https://pubmed.ncbi.nlm.nih.gov/36644878/
Fearon, K., Strasser, F., Anker, S. D., et al. (2011). Definition and classification of cancer cachexia: an international consensus. The Lancet Oncology, 12(5), 489–495. https://pubmed.ncbi.nlm.nih.gov/21296615/
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., et al. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 48(1), 16–31. https://pubmed.ncbi.nlm.nih.gov/30312372/